Literature DB >> 28459376

Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals.

Ting Liu1,2, Le Zhao3, Huilian Hou4, Lu Ding5, Wei Chen6, Xu Li3.   

Abstract

Hypoxia-inducible factor 1 is believed to play a prominent role in the survival and developing progress of cancers. As a result, inhibiting α subunit of hypoxia-inducible factor 1 represents an attractive strategy against tumor. Although hypoxia-inducible factor 1α is a hypoxia-regulated subunit, increasing evidence indicates that hypoxia-inducible factor 1α could stable expression under normoxic conditions, regulated by non-hypoxia-mediated mechanisms. However, there are few strategies to target hypoxia-inducible factor 1α under normoxic conditions. Here, we report that ginsenoside 20(S)-Rg3, one of the main active ingredients in red ginseng, restrains hypoxia-inducible factor 1α expression under normal oxygen levels in human ovarian cancer cell lines, SKOV3 and 3AO, which leads to potently inhibits migration of ovarian cancer in vitro and in vivo. 20(S)-Rg3 could decrease the expression of hypoxia-inducible factor 1α by upregulation of prolyl hydroxylase domain protein 1 to promoting hypoxia-inducible factor 1α ubiquitin-proteasome degradation under normal oxygen levels. Furthermore, 20(S)-Rg3 could attenuate the expression of nuclear factor-κ B, which may be another possible mechanism for 20(S)-Rg3 to block ovarian cancer migration. Taken together, our study suggests that 20(S)-Rg3 is a strong inhibitor of hypoxia-inducible factor 1α, which may provide a novel agent for future treatments for ovarian cancer.

Entities:  

Keywords:  20(S)-Rg3; hypoxia-inducible factor 1α; migration; nuclear factor-κ B; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28459376     DOI: 10.1177/1010428317692225

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

Review 1.  Herbal nutraceuticals: safe and potent therapeutics to battle tumor hypoxia.

Authors:  Devarajan Nalini; Jayaraman Selvaraj; Ganesan Senthil Kumar
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-13       Impact factor: 4.553

Review 2.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

3.  Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells.

Authors:  Lingqin Zhao; Huafeng Shou; Lu Chen; Wen Gao; Chenyan Fang; Ping Zhang
Journal:  Oncol Rep       Date:  2019-04-12       Impact factor: 3.906

Review 4.  Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.

Authors:  Lízbeth Ayala-Domínguez; Leslie Olmedo-Nieva; J Omar Muñoz-Bello; Adriana Contreras-Paredes; Joaquín Manzo-Merino; Imelda Martínez-Ramírez; Marcela Lizano
Journal:  Front Oncol       Date:  2019-09-27       Impact factor: 6.244

5.  The standardized Korean Red Ginseng extract and its ingredient ginsenoside Rg3 inhibit manifestation of breast cancer stem cell-like properties through modulation of self-renewal signaling.

Authors:  Jisun Oh; Hyo-Jin Yoon; Jeong-Hoon Jang; Do-Hee Kim; Young-Joon Surh
Journal:  J Ginseng Res       Date:  2018-05-17       Impact factor: 6.060

6.  Ginsenoside Rg3 and Korean Red Ginseng extract epigenetically regulate the tumor-related long noncoding RNAs RFX3-AS1 and STXBP5-AS1.

Authors:  Juyeon Ham; Dawoon Jeong; Sungbin Park; Hyeon Woo Kim; Heejoo Kim; Sun Jung Kim
Journal:  J Ginseng Res       Date:  2019-02-28       Impact factor: 6.060

Review 7.  Antitumor effects and molecular mechanisms of action of natural products in ovarian cancer.

Authors:  Yun-Bo Yan; Qing Tian; Ji-Fang Zhang; Ying Xiang
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.